Ultime notizie per Simulations Plus (NASDAQ:SLP) Azioni

Simulations Plus

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.

Simulations Plus Inc

Smooth Love Potion - United States Dollar

Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.simulations-plus.com%2F%3Fmtm_campaign%3DSPL_and_UC_NIH_Grant_to_develop_AI_Drug_Discovery%26mtm_source%3Dissuerdirect%26mtm_medium%3Dpressrelease&amp;esheet=54132470&amp;newsitemid=20241008571649&amp;lan=en-US&amp;anchor=Simulations+Plus%2C+Inc.&amp;index=1&amp;md5=0a081cc4e4c22d01bff5afaf02e19944">Simulations Plus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. The grant will be used to evaluate novel computational methods that account for water-ligand interactions in drug discovery and that integrate with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.simulations-plus.com%2Fsoftware%2Fadmetpredictor%2Fai-driven-drug-design-aidd%2F%3Fmtm_campaign%3DSPL_and_UC_NIH_Grant_to_develop_AI_Drug_Discovery%26mtm_source%3Dissuerdirect%26mtm_medium%3Dpressrelease&amp;esheet=54132470&amp;newsitemid=20241008571649&amp;lan=en-US&amp;anchor=Artificial+Intelligence-driven+Drug+Design&amp;index=2&amp;md5=85c5f141d5882c723c264d7f10f3c8ab">Artificial Intelligence-driven Drug Design</a> (AIDD) module in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.simulations-plus.com%2Fsoftware%2Fadmetpredictor%2F%3Fmtm_campaign%3DSPL_and_UC_NIH_Grant_to_develop_AI_Drug_Discovery%26mtm_source%3Dissuerdirect%26mtm_medium%3Dpressrelease&amp;esheet=54132470&amp;newsitemid=20241008571649&amp;lan=en-US&amp;anchor=ADMET+Predictor%26%23174%3B&amp;index=3&amp;md5=a883274edf2b91a49666979402e4c3ff">ADMET Predictor&#xAE;</a> to offer a first-of-its-kind ligand-based virtual screening (LBVS) solution for pharmaceutical companies.

News

Contracts

Simulations Plus And The University Of Southern California Secure NIH Grant To Develop New AI Drug Discovery Offerings

Providing a diverse range of perspectives from bullish to bearish, 2 analysts have published ratings on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Simulations Plus, presenting an average target of $51.5, a high estimate of $56.00, and a low estimate of $47.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.04%. 
<img src="https://www.benzinga.com/files/images/story/2024/1726142430_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Simulations Plus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$56.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Simulations Plus. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Simulations Plus compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Simulations Plus's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Simulations Plus's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Simulations Plus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Simulations Plus Better</h2>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Simulations Plus: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Simulations Plus showcased positive performance, achieving a revenue growth rate of 14.23% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Simulations Plus's net margin is impressive, surpassing industry averages. With a net margin of 16.92%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Simulations Plus's ROE excels beyond industry benchmarks, reaching 1.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.62%, the company showcases effective utilization of assets.
Debt Management: Simulations Plus's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Simulations Plus: 2 Analysts Share Their Views

William Blair analyst Max Smock reiterates Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Outperform.

Reiteration

William Blair Reiterates Outperform on Simulations Plus

In a new SEC filing on September 10, it was revealed that Fiedler-Kelly, Business Unit President at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000111//Archives/edgar/data/1023459/000102345924000111/0001023459-24-000111-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Fiedler-Kelly, Business Unit President at Simulations Plus, a company in the Health Care sector, just exercised stock options worth 2,250 shares of SLP stock with an exercise price of $9.71.
Simulations Plus shares are trading, exhibiting down of 0.0% and priced at $33.36 during Wednesday's morning. This values Fiedler-Kelly's 2,250 shares at $53,212.
<h3>All You Need to Know About Simulations Plus</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Unraveling the Financial Story of Simulations Plus</h3>
Revenue Growth: Simulations Plus displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately 14.23%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: With a low gross margin of 71.49%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS reflects a decline, falling below the industry average with a current EPS of 0.16.
</li>
</ul>
Debt Management: Simulations Plus's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Simulations Plus's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 69.5.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 10.12 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 37.98 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Business Unit President At Simulations Plus Exercises Options Worth $53K

Simulations Plus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slp#NASDAQ">SLP</a>) has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.
Over the past year, Simulations Plus made two major acquisitions, including the largest in its corporate history. In June 2024, the company acquired Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders for about $100 million, expanding its footprint across the drug development continuum, from pre-clinical protocols to product commercialization. This acquisition doubled Simulations Plus&#39; addressable market by adding $4 billion in revenue opportunities within the clinical simulations training, analytics and medical communications sectors.
Building on this recent acquisition, Simulations Plus is focusing on optimizing its resources and people. The company is establishing two new business units &mdash; Adaptive Learning &amp; Insights and Medical Communications &mdash; to improve client engagement. Additionally, the Regulatory Strategies unit will transition into a Regulatory Strategies Center of Excellence to enhance sales visibility and accelerate cross-selling opportunities.
These strategic moves aim to strengthen Simulations Plus&#39; position across the drug development continuum, driving growth and profitability, the company added.
Simulations Plus announced key leadership promotions. Steven Chang is elevated to president of Quantitative Systems Pharmacology following his arrival with the Immunetrics acquisition in June 2023. Jenna Rouse will lead the new Adaptive Learning &amp; Insights unit as president, having served as chief markets officer, Clinical, at Pro-ficiency. Murry Alper will become president of the new Medical Communications unit, also joining through the Pro-ficiency acquisition.
<div class="chart_embed">
<h3>Simulations Plus, Inc. Price and Consensus</h3>
<img alt="Simulations Plus, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/8a/1724680280.png" style="height:265px; width:574px" title="" />
Simulations Plus, Inc. price-consensus-chart | Simulations Plus, Inc. Quote
The company further announced the departure of Brett Howell, president of Quantitative Systems Pharmacology, and Michael Raymer, president of Clinical Simulations &amp; Medical Communications, who will leave after aiding in the transition.
Simulations Plus is a leading-edge developer of simulation software for pharmaceutical, chemical and biotechnology companies across the globe. The simulation software is used for drug discovery, development, research and regulatory submissions.
In the third quarter of fiscal 2024, the company&#39;s revenues increased 14% year over year to $18.5 million, primarily due to higher software revenues in the Clinical Pharmacology &amp; Pharmacometrics and Cheminformatics business units.
However, sales of the PBPK unit, part of the services segment, were down 10% as the temporary delays in acquiring client source data deferred the initiation of contracted projects. SLP has also opted to discontinue the quarterly cash dividend and redirect these funds towards growth initiatives to boost long-term shareholder value.
Currently, Simulations Plus carries a Zacks Rank #4 (Sell). Shares of the company have lost 19.4% compared with the sub-industry&#39;s growth of 24.7%.
</div>
&nbsp;
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6f/75438.jpg?v=1950690958" />
Image Source: Zacks Investment Research
<h2>Stocks to Consider</h2>
Manhattan Associates, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/manh#NASDAQ">MANH</a>), sporting a Zacks Rank #1 (Strong Buy) at present, has delivered an earnings surprise of 26.6%, on average, in the trailing four quarters. In the last reported quarter, MANH delivered an earnings surprise of 22.9%.
ANSYS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anss#NASDAQ">ANSS</a>), carrying a Zacks Rank #2 (Buy) at present, has delivered an earnings surprise of 4.8%, on average, in three of the trailing four quarters. In the last reported quarter, ANSS delivered an earnings surprise of 28.9%. It has a long-term earnings growth expectation of 6.4%.
Adobe Inc., carrying a Zacks Rank #2 at present, has delivered an earnings surprise of 2.7%, on average, in the trailing four quarters. In the last reported quarter, ADBE delivered an earnings surprise of 2.1%. It has a long-term earnings growth expectation of 13%.
<a href="https://www.zacks.com/stock/news/2327227/simulations-plus-slp-restructures-business-unit-post-acquisitions?cid=CS-BENZ-FT-analyst_blog|company_news_tech_sector-2327227">To read this article on Zacks.com click here.</a>

Earnings

Dividends

Small Cap

Markets

Tech

ANSS

MANH

Simulations Plus Restructures Business Unit Post-Acquisitions

Simulations Plus Releases Updated QST Software DILIsym Version X To Investigate And Predict Drug-Induced Liver Injury

Analysts' ratings for Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Simulations Plus, presenting an average target of $56.0, a high estimate of $65.00, and a low estimate of $47.00. This upward trend is evident, with the current average reflecting a 3.7% increase from the previous average price target of $54.00.
<img src="https://www.benzinga.com/files/images/story/2024/1722254459_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Simulations Plus is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$56.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Francois Brisebois</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Simulations Plus. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Simulations Plus compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Simulations Plus's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Simulations Plus's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Simulations Plus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Simulations Plus Better</h2>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>A Deep Dive into Simulations Plus's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Simulations Plus displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately 14.23%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.92%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Simulations Plus's ROE excels beyond industry benchmarks, reaching 1.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Simulations Plus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.62%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Simulations Plus

Keybanc analyst Scott Schoenhaus initiates coverage on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight rating and announces Price Target of $47.

Price Target

Initiation

Keybanc Initiates Coverage On Simulations Plus with Overweight Rating, Announces Price Target of $47

JMP Securities analyst Constantine Davides initiates coverage on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Market Perform rating.

JMP Securities Initiates Coverage On Simulations Plus with Market Perform Rating

Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.simulations-plus.com%2F%3Fmtm_campaign%3DNew_Research_Project_with_ICCS%26mtm_source%3Dissuerdirect%26mtm_medium%3Dpressrelease&amp;esheet=54093213&amp;newsitemid=20240711635669&amp;lan=en-US&amp;anchor=Simulations+Plus%2C+Inc.&amp;index=1&amp;md5=95ce81f15ba20f24286b8e7f5c706b75">Simulations Plus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded research project with the International Collaboration on Cosmetics Safety (ICCS) to evaluate the use of physiologically-based kinetic (PBK) modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients.
In a competitive bidding process, Simulations Plus was selected for its proposal to establish workflows for probabilistic PBK modeling of new chemicals based on pharmacokinetic (PK) analogs. Simulations Plus will review ICCS-provided data, select target-source pairs based on similarity criteria, build PBK models for source chemicals, and apply these in virtual populations to predict exposure for target chemicals. The results and best practices will be published.

Simulations Plus Announces New Research Project With The International Collaboration On Cosmetics Safety To Evaluate The Use Of Physiologically-Based Kinetic Modeling Approaches To Advance Animal-Free Science For Cosmetics And Other Non-Pharmaceutical Ingredients

Craig-Hallum analyst Matt Hewitt reiterates Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Buy and maintains $56 price target.

Craig-Hallum Reiterates Buy on Simulations Plus, Maintains $56 Price Target

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday.
Shares of Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) fell sharply in today's pre-market trading after the company reported third-quarter financial results and issued FY24 EPS guidance below estimates. Also, the company announced that it will discontinue its <a href="https://www.benzinga.com/quote/SLP/earnings">quarterly cash dividend</a>.
Simulations Plus shares declined 5.3% to $44.39 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>First Foundation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NASDAQ">FFWM</a>) shares tumbled 27.7% to $4.75 in pre-market trading after the company announced that affiliates of Fortress Investment Group, Canyon Partners, Strategic Value Bank Partners, and North Reef Capital have agreed to make individual investments aggregating to $228 million in the company.</li>
<li>Repay Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) shares slipped 14.1% to $8.78 in pre-market trading after the company announced pricing of its convertible notes offering.</li>
<li>Noah Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) shares declined 10.7% to $9.20 in pre-market trading after gaining over 5% on Tuesday.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) shares fell 5.5% to $24.51 in pre-market trading. NANO Nuclear Energy recently announced that it has signed a MoU to collaborate with Curio Solutions to optimize Curio&#8217;s nuclear fuel recycling capabilities for next-generation portable nuclear microreactors.</li>
<li>American Software, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSWA#NASDAQ">AMSWA</a>) shares fell 5% to $8.62 in pre-market trading.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) shares declined 4.5% to $8.30 in pre-market trading.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/equities/24/07/39594936/how-to-earn-500-a-month-from-greenbrier-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Greenbrier Stock Ahead Of Q3 Earnings</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Pre-Market Outlook

Movers

AMSWA

FFWM

NOAH

RPAY

Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

Simulations Plus shares are trading lower after the company reported Q3 financial results and issued FY24 EPS guidance below estimates. Also, the company announced that it will discontinue its quarterly cash dividend.

Simulations Plus shares are trading lower after the company reported Q3 financial results and issued FY24 EPS guidance below estimates.

Quarterly Dividend
The Simulations Plus Board of Directors has determined to discontinue the Company's quarterly cash dividend and reallocate these funds to our capital allocation strategy for investing in growth initiatives that are intended to generate long-term shareholder value. The final dividend of $0.06 per share of the Company's common stock will be paid on August 5, 2024, to shareholders of record as of July 29, 2024.

Simulations Plus Has Determined To Discontinue Its Quarterly Cash Dividend And Reallocate These Funds To Its Capital Allocation Strategy For Investing In Growth Initiatives

Fiscal 2024 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
Fiscal 2024
Guidance
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$69M - $72M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">15 - 20%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Software mix</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">55 - 60%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Services mix</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">40 - 45%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.46 - $0.48</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.54 - $0.56</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Guidance

Simulations Plus Sees FY24 EPS $0.46-$0.48 Vs $0.55 Est.; Revenue $69M-$72M Vs $70.88M Est.

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $18.54 million which beat the analyst consensus estimate of $17.96 million by 3.25 percent. This is a 14.23 percent increase over sales of $16.23 million the same period last year.

Earnings Beats

Simulations Plus Q3 Adj $0.15, Inline, Sales $18.54M Beat $17.96M Estimate

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Neutral&#8221; zone on Monday.
U.S. stocks recorded gains on Monday, with the Nasdaq Composite settling at a record level during the session. Shares of  Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) gained 2.2%, while Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) gained around 2.9% on Monday.
The technology-heavy Nasdaq jumped 18.1% in the first half of the year, while the S&amp;P 500 surged 14.5%.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, industrials, and real estate stocks recording the biggest losses on Monday. However, information technology and consumer discretionary stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by over 50 points to 39,169.52 on Monday. The S&amp;P 500 rose 0.27% at 5,475.09, while the Nasdaq Composite climbed 0.83% at 17,879.30 during Monday's session.
Investors are awaiting earnings results from MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>), Radius Recycling, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>), and Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 48.1, the index remained in the &#8220;Neutral&#8221; zone on Monday, versus a prior reading of 48.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/06/39545594/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

AAPL

MSFT

RDUS

Nasdaq Closes At Record High Led By Microsoft And Apple: Fear & Greed Index In 'Neutral' Zone

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) to report quarterly earnings at $1.50 per share on revenue of $1.01 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. MSC Industrial Direct shares gained 1.1% to $79.10 in the after-hours trading session.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) named Peter Pfreundschuh as Chief Financial Officer, effective June 28. Y-mAbs Therapeutics shares fell 2.3% to $11.56 in the after-hours trading session.</li>
<li>Analysts are expecting Radius Recycling, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>) to post a quarterly loss at $0.66 per share on revenue of $693.90 million. The company will release earnings results before the markets open. Radius Recycling shares gained 4.6% to $15.99 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) posted FY24 earnings of $0.9 per share, up from $0.6 per share in the year-ago period. The company's revenue rose to $32.2 million from $21.8 million. Fly-E Group shares fell 0.9% to $5.44 in the after-hours trading session.</li>
<li>Analysts expect Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) to post quarterly earnings at $0.15 per share on revenue of $17.96 million after the closing bell. Simulations Plus shares gained 0.7% to $46.48 in after-hours trading.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39545594/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields</a>

Equities

FLYE

YMAB

MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday

William Blair analyst Max Smock initiates coverage on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Outperform rating.

William Blair Initiates Coverage On Simulations Plus with Outperform Rating

Catalyst Watch: Disney earnings, Costco sales update, MicroStrategy split, and eyes on AI patents

Simulations Plus: Declining Margins Are A Problem

Simulations Plus (SLP) has shared an announcement. Simulations Plus, Inc. announced leadership changes to enhance its business units, including the...

Simulations Plus Announces Leadership Shake-Up and Strategy

Conestoga Capital Advisors Q2 2024 Commentary

Harding Loevner Global Small Companies Equity Q2 2024 Report

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Simulations Plus (SLP – Research Report) today and set a price target of $65.00. ...

Simulations Plus (SLP) Receives a Buy from Oppenheimer

Morgan Stanley identifies 39 stocks likely to face tax loss selling pressure

Morgan Stanley's list of tax loss selling stocks

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Simulations Plus (SLP – Research Report) and Diamedi...

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Diamedica Therapeutics (DMAC)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Simulations Plus (SLP – Research Report) today. The company's shares closed yesterday a...

Craig-Hallum Keeps Their Buy Rating on Simulations Plus (SLP)

ABNB

ACCD

ADBE

AGYS

ALTR

AMCX

AMGN

ANET

APTV

ARCH

ATKR

BDGSF

BECTY

BHTLF

BIIB

BLFS

CCOI

CELH

CHKP

CHRD

CIVI

CLOV

COST

CPNG

CPRI

CRWD

CSGP

CYRX

DAVE

DDOG

DGII

DMAC

DSGX

DVAX

ENVA

ERII

EXPE

EXPO

FICO

FIVE

FSLY

FTNT

FWRD

GILD

GOOG

GOOGL

GWRE

HESM

HTLF

IIIN

IRDM

ISPO

KYYWF

KYYWY

LIDR

LMAT

LSPD

LUMN

MLAB

MMSI

MNESP

MNST

MSTR

NBIX

NVEE

PARAA

PLAB

POOL

PRGO

PRVA

PTEN

PYCR

QTWO

RGEN

ROCK

RTMVF

RTMVY

SHOP

SILK

SITE

SKYW

SMCI

SMPL

SPTM

SPXC

SSTI

STVN

TALO

THRM

TKNO

TREX

TRNS

TTWO

UBER

UMBF

USPH

VEEV

VRSK

VZIO

WKME

WULF

XLRE

XPEL

YUGVF

Press Releases

Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit

Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results

Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety

Simulations Plus to Participate in KeyBanc's 25th Annual Technology Leadership Forum

Simulations Plus Releases ADMET Predictor® Version 12

Simulations Plus Releases DILIsym® X

Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions

Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings

Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date

Comments

Simulations Plus

Notizie

Ultime notizie per Simulations Plus (NASDAQ:SLP) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO